Literature DB >> 24732438

Preventing non bacteremic pneumococcal pneumonia in older adults: historical background and considerations for choosing between PCV13 and PPV23.

David S Fedson1.   

Abstract

Entities:  

Keywords:  herd protection; pneumococcal conjugate vaccine; pneumococcal pneumonia; pneumococcal polysaccharide vaccine

Mesh：

Substances：

Year:  2014        PMID： 24732438      PMCID： PMC4896573          DOI： 10.4161/hv.28797

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


× No keyword cloud information.
  53 in total

1.  Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people.

Authors:  J E Sisk; A J Moskowitz; W Whang; J D Lin; D S Fedson; A M McBean; J F Plouffe; M S Cetron; J C Butler
Journal:  JAMA       Date:  1997 Oct 22-29       Impact factor: 56.272

2.  Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.

Authors:  Anneke Steens; Marianne A Riise Bergsaker; Ingeborg S Aaberge; Karin Rønning; Didrik F Vestrheim
Journal:  Vaccine       Date:  2013-10-29       Impact factor: 3.641

3.  The stubborn persistence of adult pneumococcal pneumonia as a public health problem.

Authors:  Rosalind Hollingsworth; Raul Isturiz
Journal:  Hum Vaccin Immunother       Date:  2014-02-19       Impact factor: 3.452

4.  When was a "negative" clinical trial big enough? How many patients you needed depends on what you found.

Authors:  A S Detsky; D L Sackett
Journal:  Arch Intern Med       Date:  1985-04

5.  Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020.

Authors:  Ruth Link-Gelles; Thomas Taylor; Matthew R Moore
Journal:  Vaccine       Date:  2013-04-11       Impact factor: 3.641

6.  Cost effectiveness of child pneumococcal conjugate vaccination in middle-income countries.

Authors:  Mari M Nakamura; Azadeh Tasslimi; Tracy A Lieu; Orin Levine; Maria Deloria Knoll; Louise B Russell; Anushua Sinha
Journal:  Int Health       Date:  2011-12       Impact factor: 2.473

7.  Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children.

Authors:  F Angoulvant; C Levy; E Grimprel; E Varon; M Lorrot; S Biscardi; P Minodier; M A Dommergues; L Hees; Y Gillet; I Craiu; F Zenkhri; F Dubos; C Gras-Le Guen; E Launay; A Martinot; R Cohen
Journal:  Clin Infect Dis       Date:  2014-02-13       Impact factor: 9.079

Review 8.  Systematic review of the indirect effect of pneumococcal conjugate vaccine dosing schedules on pneumococcal disease and colonization.

Authors:  Jennifer D Loo; Laura Conklin; Katherine E Fleming-Dutra; Maria Deloria Knoll; Daniel E Park; Jennifer Kirk; David Goldblatt; Katherine L O'Brien; Cynthia G Whitney
Journal:  Pediatr Infect Dis J       Date:  2014-01       Impact factor: 2.129

9.  Pneumococcal serotypes in adult non-invasive and invasive pneumonia in relation to child contact and child vaccination status.

Authors:  Chamira Rodrigo; Thomas Bewick; Carmen Sheppard; Sonia Greenwood; Vanessa Macgregor; Caroline Trotter; Mary Slack; Robert George; Wei Shen Lim
Journal:  Thorax       Date:  2013-09-18       Impact factor: 9.139

10.  Impact of the 7-valent pneumococcal conjugate vaccine on the incidence of childhood pneumonia.

Authors:  M A Elemraid; S P Rushton; M D F Shirley; M F Thomas; D A Spencer; K M Eastham; F Hampton; R Gorton; K Pollard; A R Gennery; J E Clark
Journal:  Epidemiol Infect       Date:  2012-10-19       Impact factor: 2.451
View more
  8 in total

Review 1.  Economic Evidence of Pneumococcal Vaccination in Older Adults: Uncertain Modelling or Competitive Tendering?

Authors:  Livio Garattini; Anna Padula; Milene Rangel Da Costa
Journal:  Pharmacoeconomics       Date:  2016-03       Impact factor: 4.981

2.  Peripheral CD4 T follicular cells induced by a conjugated pneumococcal vaccine correlate with enhanced opsonophagocytic antibody responses in younger individuals.

Authors:  Sarah Sterrett; Binghao J Peng; Robert L Burton; David C LaFon; Andrew O Westfall; Suddham Singh; Michael Pride; Annaliesa S Anderson; Gregory C Ippolito; Harry W Schroeder; Moon H Nahm; A Krishna Prasad; Paul Goepfert; Anju Bansal
Journal:  Vaccine       Date:  2020-01-03       Impact factor: 3.641

3.  The Influence of Influenza and Pneumococcal Vaccines on Community-Acquired Pneumonia (CAP) Outcomes Among Elderly Patients.

Authors:  Paul O Gubbins; Chenghui Li
Journal:  Curr Infect Dis Rep       Date:  2015-12       Impact factor: 3.725

Review 4.  Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis.

Authors:  Gerhard Falkenhorst; Cornelius Remschmidt; Thomas Harder; Eva Hummers-Pradier; Ole Wichmann; Christian Bogdan
Journal:  PLoS One       Date:  2017-01-06       Impact factor: 3.240

Review 5.  Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations.

Authors:  Yang Wang; Jingxin Li; Yuxiao Wang; Wei Gu; Fengcai Zhu
Journal:  Hum Vaccin Immunother       Date:  2017-12-21       Impact factor: 3.452

6.  Determinants of tetanus, pneumococcal and influenza vaccination in the elderly: a representative cross-sectional study on knowledge, attitude and practice (KAP).

Authors:  Carolina J Klett-Tammen; Gérard Krause; Linda Seefeld; Jördis J Ott
Journal:  BMC Public Health       Date:  2016-02-04       Impact factor: 3.295

7.  Pneumococcal Disease and the Effectiveness of the PPV23 Vaccine in Adults: A Two-Stage Bayesian Meta-Analysis of Observational and RCT Reports.

Authors:  Hamid Latifi-Navid; Saeid Latifi-Navid; Behdad Mostafaiy; Sadegh Azimzadeh Jamalkandi; Ali Ahmadi
Journal:  Sci Rep       Date:  2018-07-23       Impact factor: 4.379

8.  [Antipneumococcal vaccination in Catalonian adults: Vaccine coverages and adequacy to distinct guideline recommendations].

Authors:  Olga Ochoa-Gondar; Ángel Vila-Córcoles; Cinta de Diego; Eva Satué; Angel Vila-Rovira; María Aragón
Journal:  Aten Primaria       Date:  2018-01-17       Impact factor: 1.137
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.